First Gen CAR T Cells

This podcast delves into the exciting world of cancer immunotherapy, focusing on the evolution of cancer vaccines and the recent surge of cell-based therapies. This series follows a string of primary research papers highlighting the most impactful advances in CAR T Cell therapy. It is a companion to a KU Edwards Campus Biotechnology course, but it contains information interesting to anyone who wants to understand the mechanics of this therapy. It begins with a 2003 Nature Biotechnology paper by Maher et al. that combines CD3 and CD28 signaling domains together on a single chimeric antigen receptor. A second paper from the 2004 journal, Leukemia, by Imai et al., looks at another receptor’s signaling domain, 4-1BB, as an alternative strategy to overcoming AICD in CAR T Cells.